Revvity, Inc. (RVTY)

NYSE · Diagnostics & Research

114.80
-1.38 (-1.18%)
Updated Aug 18, 3:30 PM ET
AI Rating
Buy
Overall Score
74
Trend
75
Momentum
80
Risk
65

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Feb 24, 2026 120 sessions Aug 14, 2026

AI Analysis

Revvity, Inc. is trading at $114.80, down 1.18% on the session. The 50 day average sits at $109.34 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 59.5, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $108.02 with resistance near $117.37, so that band frames the current range. Average daily movement is roughly $3.62, or about 3.2% of the share price, which is what any stop placement has to allow for. The overall health score of 74 out of 100 combines a trend score of 75, momentum of 80 and a risk score of 65.

Technical indicators

RSI (14)
59.5
strong
MACD
2.199
bullish crossover
SMA 20
113.23
SMA 50
109.34
SMA 200
--
unknown
ATR (14)
3.62
avg daily range
Support
108.02
Resistance
117.37
Volume vs 20d
0.49x
below average
Volatility
34.0%
annualised
1 month
+4.60%
3 months
+21.23%

About Revvity, Inc.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.